{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:22:28Z","timestamp":1792664548969,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11325-019-01894-4","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T06:27:00Z","timestamp":1562740020000},"page":"615-627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Narcolepsy treatment: pharmacological and behavioral strategies in adults and children"],"prefix":"10.1007","volume":"24","author":[{"given":"Christian","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Antelmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia","family":"Folli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-5209","authenticated-orcid":false,"given":"Giuseppe","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"1894_CR1","volume-title":"ICSD-3: international classification of sleep disorders","author":"AASM: American Academy of Sleep Medicine","year":"2014","unstructured":"AASM: American Academy of Sleep Medicine (2014) ICSD-3: international classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Daniel","edition":"3"},{"key":"1894_CR2","doi-asserted-by":"publisher","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","volume":"96","author":"JJ Hagan","year":"1999","unstructured":"Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DNC, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. PNAS 96:10911\u201310916. https:\/\/doi.org\/10.1073\/pnas.96.19.10911","journal-title":"PNAS"},{"key":"1894_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1","volume":"62","author":"JG Sutcliffe","year":"2000","unstructured":"Sutcliffe JG, de Lecea L (2000) The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62:161\u2013168. https:\/\/doi.org\/10.1002\/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1","journal-title":"J Neurosci Res"},{"key":"1894_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0028-3908(00)00178-7","volume":"40","author":"RE Brown","year":"2001","unstructured":"Brown RE, Sergeeva O, Eriksson KS, Haas H (2001) Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 40:457\u2013459. https:\/\/doi.org\/10.1016\/S0028-3908(00)00178-7","journal-title":"Neuropharmacology"},{"key":"1894_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.prrv.2016.12.005","volume":"25","author":"TJ Dye","year":"2018","unstructured":"Dye TJ, Gurbani N, Simakajornboon N (2018) Epidemiology and pathophysiology of childhood narcolepsy. Paediatr Respir Rev 25:14\u201318. https:\/\/doi.org\/10.1016\/j.prrv.2016.12.005","journal-title":"Paediatr Respir Rev"},{"key":"1894_CR6","doi-asserted-by":"publisher","unstructured":"Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, Ueta Y (2008) Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neuroscience research, 61-99-105. https:\/\/doi.org\/10.1016\/j.neures.2008.01.017","DOI":"10.1016\/j.neures.2008.01.017"},{"key":"1894_CR7","first-page":"228","volume":"1","author":"T Tashiro","year":"1992","unstructured":"Tashiro T, Kanbayashi T, Iijima S, Hishikawa Y (1992) An epidemiological study of narcolepsy in Japanese. J Sleep Res 1:228","journal-title":"J Sleep Res"},{"key":"1894_CR8","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1212\/WNL.50.2_Suppl_1.S16","volume":"50","author":"E Mignot","year":"1998","unstructured":"Mignot E (1998) Genetic and familial aspects of narcolepsy. Neurology 50:S16\u2013S22. https:\/\/doi.org\/10.1212\/WNL.50.2_Suppl_1.S16","journal-title":"Neurology"},{"key":"1894_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.5665\/sleep.3756","volume":"37","author":"CR Baumann","year":"2014","unstructured":"Baumann CR, Mignot E, Lammers GJ, Overeem S, Arnulf I, Rye D, Dauvilliers Y, Honda M, Owens JA, Plazzi G, Scammell TE (2014) Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37:1035\u20131042. https:\/\/doi.org\/10.5665\/sleep.3756","journal-title":"Sleep"},{"key":"1894_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41439-018-0033-7","volume":"6","author":"T Miyagawa","year":"2019","unstructured":"Miyagawa T, Tokunaga K (2019) Genetics of narcolepsy. Hum Genome Var 6:4. https:\/\/doi.org\/10.1038\/s41439-018-0033-7","journal-title":"Hum Genome Var"},{"key":"1894_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.smrv.2017.04.003","volume":"38","author":"E Postiglione","year":"2018","unstructured":"Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G (2018) The clinical spectrum of childhood narcolepsy. Sleep Med Rev 38:70\u201385. https:\/\/doi.org\/10.1016\/j.smrv.2017.04.003","journal-title":"Sleep Med Rev"},{"key":"1894_CR12","doi-asserted-by":"publisher","first-page":"e38977","DOI":"10.1371\/journal.pone.0038977","volume":"7","author":"Y Dauvilliers","year":"2012","unstructured":"Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, Levy P, Pepin JL (2012) Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 7:e38977. https:\/\/doi.org\/10.1371\/journal.pone.0038977","journal-title":"PLoS One"},{"key":"1894_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.sleep.2011.01.013","volume":"12","author":"HA Fortuyn","year":"2011","unstructured":"Fortuyn HA, Mulders PC, Renier WO, Buitelaar JK, Overeem S (2011) Narcolepsy and psychiatry: an evolving association of increasing interest. Sleep Med 12:714\u2013719. https:\/\/doi.org\/10.1016\/j.sleep.2011.01.013","journal-title":"Sleep Med"},{"key":"1894_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0035-1550152","volume":"46","author":"FL Rocca","year":"2015","unstructured":"Rocca FL, Pizza F, Ricc E, Plazzi G (2015) Narcolepsy during childhood: an update. Neuropediatrics 46:181\u2013198. https:\/\/doi.org\/10.1055\/s-0035-1550152","journal-title":"Neuropediatrics"},{"key":"1894_CR15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.sleep.2012.08.002","volume":"13","author":"F Ingravallo","year":"2012","unstructured":"Ingravallo F, Gnucci V, Pizza F, Vignatelli L, Govi A, Dormi A, Pelotti S, Cicognani A, Dauvilliers Y, Plazzi G (2012) The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med 13:1293\u20131300. https:\/\/doi.org\/10.1016\/j.sleep.2012.08.002","journal-title":"Sleep Med"},{"key":"1894_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.slsci.2014.07.001","volume":"7","author":"TG Ton","year":"2014","unstructured":"Ton TG, Watson NF, Koepsell TD, Longstreth WT (2014) Narcolepsy and the sickness impact profile: a general health status measure. Sleep Sci 7:5\u201312. https:\/\/doi.org\/10.1016\/j.slsci.2014.07.001","journal-title":"Sleep Sci"},{"key":"1894_CR17","doi-asserted-by":"publisher","first-page":"8620","DOI":"10.1523\/JNEUROSCI.20-22-08620.2000","volume":"20","author":"TE Scammell","year":"2000","unstructured":"Scammell TE, Estabrooke IV, McCarthy MT et al (2000) Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20:8620\u20138628. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-22-08620.2000","journal-title":"J Neurosci"},{"key":"1894_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fneur.2013.00139","volume":"4","author":"J Wisor","year":"2013","unstructured":"Wisor J (2013) Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol 4:139. https:\/\/doi.org\/10.3389\/fneur.2013.00139","journal-title":"Front Neurol"},{"key":"1894_CR19","doi-asserted-by":"publisher","unstructured":"Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Pollm\u00e4cher T, Reading P, Sonka K; EFNS Task Force (2006) EFNS Task Force. EFNS guidelines on management of narcolepsy. Eur J Neurol 13:1035\u20131048. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01473.x","DOI":"10.1111\/j.1468-1331.2006.01473.x"},{"key":"1894_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1750","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T et al (2007) Standards of practice committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30:1705\u20131711. https:\/\/doi.org\/10.1093\/sleep\/30.12.1750","journal-title":"Sleep"},{"key":"1894_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1176\/jnp.17.3.405","volume":"17","author":"JR Schwartz","year":"2005","unstructured":"Schwartz JR, Feldman NT, Bogan RK (2005) Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry ClinNeurosci 17:405\u2013412. https:\/\/doi.org\/10.1176\/jnp.17.3.405","journal-title":"J Neuropsychiatry ClinNeurosci"},{"key":"1894_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","volume":"26","author":"JR Schwartz","year":"2003","unstructured":"Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ (2003) Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 26:252\u2013257","journal-title":"Clin Neuropharmacol"},{"key":"1894_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00002826-200403000-00005","volume":"27","author":"JR Schwartz","year":"2004","unstructured":"Schwartz JR, Nelson MT, Schwartz ER, Hughes RJ (2004) Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 27:74\u201379","journal-title":"Clin Neuropharmacol"},{"key":"1894_CR24","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","volume":"17","author":"M Billiard","year":"1994","unstructured":"Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, Lubin S (1994) Modafinil: a double-blind multicentric study. Sleep 17:S107\u2013S112","journal-title":"Sleep"},{"key":"1894_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.49.2.444","volume":"49","author":"RJ Broughton","year":"1997","unstructured":"Broughton RJ, Fleming JA, George CF et al (1997) Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49:444\u2013451","journal-title":"Neurology"},{"key":"1894_CR26","doi-asserted-by":"publisher","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group (2000). Neurology 54:1166\u20131175. https:\/\/doi.org\/10.1212\/WNL.54.5.1166","DOI":"10.1212\/WNL.54.5.1166"},{"key":"1894_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/sleep\/22.6.757","volume":"22","author":"KM Beusterien","year":"1999","unstructured":"Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L, Goswami M, Steinwald B (1999) Health- related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22:757\u2013765","journal-title":"Sleep"},{"key":"1894_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2125.2000.00271.x","volume":"50","author":"S Palovaara","year":"2000","unstructured":"Palovaara S, Kivist\u00f6 KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K (2000) Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam l-hydroxylation. Br J Clin Pharm 50:333\u2013337. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00271.x","journal-title":"Br J Clin Pharm"},{"key":"1894_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11940-015-0347-4","volume":"18","author":"U Kallweit","year":"2017","unstructured":"Kallweit U, Bassetti CL (2017) Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother 18:809\u2013817. https:\/\/doi.org\/10.1007\/s11940-015-0347-4","journal-title":"Expert Opin Pharmacother"},{"key":"1894_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1185\/030079906X100050","volume":"22","author":"JR Harsh","year":"2006","unstructured":"Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T (2006) The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22:761\u2013774. https:\/\/doi.org\/10.1185\/030079906X100050","journal-title":"Curr Med Res Opin"},{"key":"1894_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"J-S Lin","year":"2008","unstructured":"Lin J-S, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients. Neurobiol Dis 30:74\u201383. https:\/\/doi.org\/10.1016\/j.nbd.2007.12.003","journal-title":"Neurobiol Dis"},{"key":"1894_CR32","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomized trial. Lancet Neurol 12:1068\u20131075. https:\/\/doi.org\/10.1016\/S1474-4422(13)70225-4","journal-title":"Lancet Neurol"},{"key":"1894_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","volume":"16","author":"Z Szakacs","year":"2017","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, Poluektov M, Yakupov E, Kalinkin A, Aksu M, Yilmaz H, Benbir G, Wolynczyk-Gmaj D, Jernajczyk W, Staykov I, Tavarari AN (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200\u2013207. https:\/\/doi.org\/10.1016\/S1474-4422(16)30333-7","journal-title":"Lancet Neurol"},{"key":"1894_CR34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY (2016) Pitolisant: first global approval. Drugs 76:1313\u20131318. https:\/\/doi.org\/10.1007\/s40265-016-0620-1","journal-title":"Drugs"},{"key":"1894_CR35","first-page":"273","volume":"12","author":"M Mamelak","year":"1977","unstructured":"Mamelak M, Escriu JM, Stokan O (1977) The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 12:273\u2013288","journal-title":"Biol Psychiatry"},{"key":"1894_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/jsr.12468","volume":"26","author":"T Roth","year":"2017","unstructured":"Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J (2017) Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res 26:407\u2013414. https:\/\/doi.org\/10.1111\/jsr.12468","journal-title":"J Sleep Res"},{"key":"1894_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.smrv.2004.01.004","volume":"8","author":"WC Houghton","year":"2004","unstructured":"Houghton WC, Scammell TE, Thorpy M (2004) Pharmacotherapy for cataplexy. Sleep Med Rev 8:355\u2013366. https:\/\/doi.org\/10.1016\/j.smrv.2004.01.004","journal-title":"Sleep Med Rev"},{"key":"1894_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.sleep.2011.10.032","volume":"13","author":"M Mansukhani","year":"2012","unstructured":"Mansukhani M, Kotagal S (2012) Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study. Sleep Med 13:606\u2013610. https:\/\/doi.org\/10.1016\/j.sleep.2011.10.032","journal-title":"Sleep Med"},{"key":"1894_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Y Dauvilliers","year":"2004","unstructured":"Dauvilliers Y, Carlander B, Rivier F (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905\u2013908. https:\/\/doi.org\/10.1002\/ana.20339","journal-title":"Ann Neurol"},{"key":"1894_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/14651858.CD006685.pub4.2016","volume":"25","author":"MM de Oliveira","year":"2016","unstructured":"de Oliveira MM, Conti C, Prado GF (2016) Pharmacological treatment for Kleine Levin syndrome. Cochrane Database Syst Rev 25:486\u2013496. https:\/\/doi.org\/10.1002\/14651858.CD006685.pub4.2016","journal-title":"Cochrane Database Syst Rev"},{"key":"1894_CR41","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1212\/WNL.0000000000002104","volume":"85","author":"S Leu-Semenescu","year":"2015","unstructured":"Leu-Semenescu S, Le Corvec T, Groos E, Lavault S, Golmard JL, Arnulf I (2015) Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology 85:1655\u20131662. https:\/\/doi.org\/10.1212\/WNL.0000000000002104","journal-title":"Neurology"},{"key":"1894_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ana.24459","volume":"78","author":"LM Trotti","year":"2015","unstructured":"Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, Rye DB (2015) Clarithromycin in \u0263-aminobutyric acid-related hypersomnolence: a randomized, cross-over trial. Ann Neurol 78:454\u2013465. https:\/\/doi.org\/10.1002\/ana.24459","journal-title":"Ann Neurol"},{"key":"1894_CR43","unstructured":"PDR.net (2016) Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm332029.htm"},{"key":"1894_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/sleep\/9.1.260","volume":"9","author":"MM Mitler","year":"1986","unstructured":"Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP (1986) Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9:260\u2013264. https:\/\/doi.org\/10.1093\/sleep\/9.1.260","journal-title":"Sleep"},{"key":"1894_CR45","first-page":"288","volume":"25","author":"Y Honda","year":"1979","unstructured":"Honda Y, Hishikawa Y, Takahashi Y (1979) Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res 25:288\u2013298","journal-title":"Curr Ther Res"},{"key":"1894_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/hup.579","volume":"19","author":"BE Leonard","year":"2004","unstructured":"Leonard BE, McCartan D, White J, King DJ (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151\u2013180. https:\/\/doi.org\/10.1002\/hup.579","journal-title":"Hum Psychopharmacol"},{"key":"1894_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","volume":"9","author":"EJ Mignot","year":"2012","unstructured":"Mignot EJ (2012) A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 9:739\u2013752. https:\/\/doi.org\/10.1007\/s13311-012-0150-9","journal-title":"Neurotherapeutics"},{"key":"1894_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00002826-199508000-00002","volume":"18","author":"G Mayer","year":"1995","unstructured":"Mayer G, Meier-Ewert K, Hephata K (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18:306\u2013319","journal-title":"Clin Neuropharmacol"},{"key":"1894_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","volume":"24","author":"O Larrosa","year":"2001","unstructured":"Larrosa O, de la Llave Y, Barrio S, Granizo JJ, Garcia-Borreguero D (2001) Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24:282\u2013285. https:\/\/doi.org\/10.1093\/sleep\/24.3.282","journal-title":"Sleep"},{"key":"1894_CR50","doi-asserted-by":"publisher","first-page":"e53707","DOI":"10.1371\/journal.pone.0053707","volume":"8","author":"T Miyagawa","year":"2013","unstructured":"Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, Inoue Y, Honda M (2013) Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One 8:e53707. https:\/\/doi.org\/10.1371\/journal.pone.0053707","journal-title":"PLoS One"},{"key":"1894_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","volume":"18","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y (2016) Management of narcolepsy. Curr Treat Opin Neurol 18:43. https:\/\/doi.org\/10.1007\/s11940-016-0429-y","journal-title":"Curr Treat Opin Neurol"},{"key":"1894_CR52","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bmj.290.6476.1167","volume":"290","author":"J Shindler","year":"1985","unstructured":"Shindler J, Schachter M, Brincat S, Parkes JD (1985) Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 290:1167\u20131170","journal-title":"BMJ"},{"key":"1894_CR53","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0140-6736(91)92966-6","volume":"337","author":"B Alvarez","year":"1991","unstructured":"Alvarez B, Dahlitz M, Grimshaw J, Parkes JD (1991) Mazindol in long-term treatment of narcolepsy. Lancet Lond Engl 337:1293\u20131294","journal-title":"Lancet Lond Engl"},{"key":"1894_CR54","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y (2019) A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 85:359\u2013370. https:\/\/doi.org\/10.1002\/ana.25423","journal-title":"Ann Neurol"},{"key":"1894_CR55","unstructured":"Sleepfoundation.org (2019) Sleep apnea | National Sleep Foundation. [online] Available: https:\/\/www.sleepfoundation.org\/sleep-disorders-problems\/sleep-apnea"},{"key":"1894_CR56","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.smrv.2011.09.001","volume":"16","author":"R Boscolo-Berto","year":"2012","unstructured":"Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y (2012) Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 16:431\u2013443. https:\/\/doi.org\/10.1016\/j.smrv.2011.09.001","journal-title":"Sleep Med Rev"},{"key":"1894_CR57","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5664\/jcsm.2048","volume":"8","author":"MK Alshaikh","year":"2012","unstructured":"Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (2012) Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 8:451\u2013458. https:\/\/doi.org\/10.5664\/jcsm.2048","journal-title":"J Clin Sleep Med"},{"key":"1894_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0006-3223(89)90048-6","volume":"26","author":"L Scrima","year":"1989","unstructured":"Scrima L, Hartman PG, Johnson FH Jr, Hiller FC (1989) Efficacy of gammahydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 26:331\u2013343","journal-title":"Biol Psychiatry"},{"key":"1894_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/sleep\/16.3.216","volume":"16","author":"GJ Lammers","year":"1993","unstructured":"Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J (1993) Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16:216\u2013220. https:\/\/doi.org\/10.1093\/sleep\/16.3.216","journal-title":"Sleep"},{"key":"1894_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/sleep\/25.1.42","volume":"25","author":"US Xyrem Multicenter Study Group","year":"2002","unstructured":"US Xyrem Multicenter Study Group (2002) A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25:42\u201349. https:\/\/doi.org\/10.1093\/sleep\/25.1.42","journal-title":"Sleep"},{"key":"1894_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/sleep\/26.1.31","volume":"26","author":"US Xyrem Multicenter Study Group","year":"2003","unstructured":"US Xyrem Multicenter Study Group (2003) A 12-month, open- label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26:31\u201335. https:\/\/doi.org\/10.1093\/sleep\/26.1.31","journal-title":"Sleep"},{"key":"1894_CR62","doi-asserted-by":"publisher","unstructured":"Mayer G, Plazzi G, Iranzo \u00c1, Ortega-Alb\u00e1s J, Quinnell T, Pesch H, Serralheiro P, Schlit AF, Wuiame D, Bentz JWG (2018) Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep 41(9). https:\/\/doi.org\/10.1093\/sleep\/zsy128","DOI":"10.1093\/sleep\/zsy128"},{"key":"1894_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11940-017-0459-0","volume":"19","author":"S Pillen","year":"2017","unstructured":"Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S (2017) Cataplexy and its mimics: clinical recognition and management. Curr Treat Options Neurol 19:23. https:\/\/doi.org\/10.1007\/s11940-017-0459-0","journal-title":"Curr Treat Options Neurol"},{"key":"1894_CR64","doi-asserted-by":"publisher","first-page":"715","DOI":"10.5664\/jcsm.2848","volume":"15","author":"J Wang","year":"2013","unstructured":"Wang J, Greenberg H (2013) Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med 15:715\u2013716. https:\/\/doi.org\/10.5664\/jcsm.2848","journal-title":"J Clin Sleep Med"},{"key":"1894_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","volume":"33","author":"M Kollb-Sielecka","year":"2017","unstructured":"Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M (2017) The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med 33:125\u2013129. https:\/\/doi.org\/10.1016\/j.sleep.2017.01.002","journal-title":"Sleep Med"},{"key":"1894_CR66","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","volume":"16","author":"Z Szakacs","year":"2017","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V et al (2017) HARMONY-CTP study group. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200\u2013207. https:\/\/doi.org\/10.1016\/S1474-4422(16)30333-7","journal-title":"Lancet Neurol"},{"key":"1894_CR67","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","volume":"9","author":"N Langdon","year":"1986","unstructured":"Langdon N, Bandak S, Shindler J, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9:371\u2013372. https:\/\/doi.org\/10.1093\/sleep\/9.2.371","journal-title":"Sleep"},{"key":"1894_CR68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1212\/WNL.44.4.707","volume":"44","author":"J Frey","year":"1994","unstructured":"Frey J, Darbonne C (1994) Fluoxetine suppresses human cataplexy: a pilot study. Neurology 44:707\u2013709","journal-title":"Neurology"},{"key":"1894_CR69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1389-9457(00)00026-5","volume":"1","author":"SS Thirumalai","year":"2000","unstructured":"Thirumalai SS, Shubin RA (2000) The use of citalopram in resistant cataplexy. Sleep Med 1:313\u2013316. https:\/\/doi.org\/10.1016\/S1389-9457(00)00026-5","journal-title":"Sleep Med"},{"key":"1894_CR70","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1212\/01.wnl.0000175978.61048.62","volume":"65","author":"R Poryazova","year":"2005","unstructured":"Poryazova R, Siccoli M, Werth E, Basssetti CL (2005) Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 65:967\u2013968. https:\/\/doi.org\/10.1212\/01.wnl.0000175978.61048.62","journal-title":"Neurology"},{"key":"1894_CR71","first-page":"171","volume":"43","author":"M Schachter","year":"1980","unstructured":"Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. JNNP 43:171\u2013174","journal-title":"JNNP"},{"key":"1894_CR72","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/archneur.1975.00490520023002","volume":"32","author":"WR Shapiro","year":"1975","unstructured":"Shapiro WR (1975) Treatment of cataplexy with clomipramine. Arch Neurol 32:653\u2013656. https:\/\/doi.org\/10.1001\/archneur.1975.00490520023002","journal-title":"Arch Neurol"},{"key":"1894_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1600-0404.1976.tb07621.x","volume":"54","author":"C Guilleminault","year":"1976","unstructured":"Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W (1976) Evaluation of shortterm and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 54:71\u201387. https:\/\/doi.org\/10.1111\/j.1600-0404.1976.tb07621.x","journal-title":"Acta Neurol Scand"},{"key":"1894_CR74","first-page":"293","volume":"3","author":"T Rugino","year":"2007","unstructured":"Rugino T (2007) A review of modafinil film-coated tablets for attention deficit\/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 3:293\u2013301","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1894_CR75","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s13311-012-0149-2","volume":"4","author":"A Ivanenko","year":"2003","unstructured":"Ivanenko A, Tauman R, Gozal D (2003) Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 4:579\u2013582. https:\/\/doi.org\/10.1007\/s13311-012-0149-2","journal-title":"Sleep Med"},{"key":"1894_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","volume":"35","author":"CO Inocente","year":"2012","unstructured":"Inocente CO, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reim\u00e3o R, Lin JS, Franco P (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. ClinNeuropharmacol 35:55\u201360. https:\/\/doi.org\/10.1097\/WNF.0b013e318246879d","journal-title":"ClinNeuropharmacol"},{"key":"1894_CR77","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2174\/1389200219666180305153134","volume":"19","author":"M Moresco","year":"2018","unstructured":"Moresco M, Pizza F, Antelmi E, Plazzi G (2018) Sodium oxybate treatment in pediatric type 1 narcolepsy. Curr Drug Metab 19:1073\u20131079. https:\/\/doi.org\/10.2174\/1389200219666180305153134","journal-title":"Curr Drug Metab"},{"key":"1894_CR78","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/sleep\/29.8.1025","volume":"29","author":"H Murali","year":"2006","unstructured":"Murali H, Kotagal S (2006) Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29:1025\u20131029. https:\/\/doi.org\/10.1093\/sleep\/29.8.1025","journal-title":"Sleep"},{"key":"1894_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2018.06.008","volume":"85","author":"G Plazzi","year":"2018","unstructured":"Plazzi G, Clawges HM, Owens JA (2018) Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol 85:21\u201332. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2018.06.008","journal-title":"Pediatr Neurol"},{"key":"1894_CR80","unstructured":"FDA approves new treatment of cataplexy and excessive daytime sleepiness in pediatric patients with narcolepsy- drug information update [news release] (2018) Silver Spring, MD: FDA Division of Drug Information"},{"key":"1894_CR81","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-3-319-23739-8_22","volume-title":"Narcolepsy. A clinical guide","author":"S Nishino","year":"2016","unstructured":"Nishino S, Kotorii N (2016) Modes of action of drugs related to narcolepsy:pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Thorpy MJ, Pandi-Perumal SR (eds) Narcolepsy. A clinical guide. Springer International Publishing, Switzerland, pp 307\u2013329"},{"key":"1894_CR82","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1592\/phco.29.6.656","volume":"29","author":"JA Dopheide","year":"2009","unstructured":"Dopheide JA, Pilszka SR (2009) Attention-deficit disorder: an update. Pharmacotherapy 29:656\u2013679","journal-title":"Pharmacotherapy"},{"key":"1894_CR83","unstructured":"Product information (2007) Dextroamphetamine sulfate oral tablets, dextroamphetamine sulfate oral tablets. St. Louis: Mallinckrodt; 2007"},{"key":"1894_CR84","unstructured":"Product information (2007) RITALIN: oral tablets, methylphenidate hydrochloride oral tablets. East Hanover, NJ: Novartis; 2007"},{"key":"1894_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.prrv.2017.06.012","volume":"25","author":"S Kotagal","year":"2018","unstructured":"Kotagal S (2018) Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev 25:19\u201324. https:\/\/doi.org\/10.1016\/j.prrv.2017.06.012","journal-title":"Paediatr Respir Rev"},{"key":"1894_CR86","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.sleep.2008.04.004","volume":"10","author":"RK Ristanovic","year":"2009","unstructured":"Ristanovic RK, Llang H, Hornfeldt CS, Lai C (2009) Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy. Sleep Med 10:416\u2013421. https:\/\/doi.org\/10.1016\/j.sleep.2008.04.004","journal-title":"Sleep Med"},{"key":"1894_CR87","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14656566.2013.783021","volume":"14","author":"R Lopez","year":"2013","unstructured":"Lopez R, Dauvilliers Y (2013) Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 14:895\u2013903. https:\/\/doi.org\/10.1517\/14656566.2013.783021","journal-title":"Expert Opin Pharmacother"},{"key":"1894_CR88","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.5664\/jcsm.3284","volume":"15","author":"M Ratkiewicz","year":"2013","unstructured":"Ratkiewicz M, Splaingard M (2013) Treatment of cataplexy in a three-year-old using venlafaxine. J Clin Sleep Med 15:1341\u20131342. https:\/\/doi.org\/10.5664\/jcsm.3284","journal-title":"J Clin Sleep Med"},{"key":"1894_CR89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/cap.2008.036","volume":"19","author":"L Moller","year":"2009","unstructured":"Moller L, Ostergaard J (2009) Treatment with venlafaxine in six cases of children with narcolepsy with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 19:197\u2013201. https:\/\/doi.org\/10.1089\/cap.2008.036","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1894_CR90","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","volume":"255","author":"G Plazzi","year":"2008","unstructured":"Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, Mignot E, Cicognani A, Montagna P (2008) Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 255:1549\u20131554. https:\/\/doi.org\/10.1007\/s00415-008-0983-7","journal-title":"J Neurol"},{"key":"1894_CR91","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1212\/WNL.0b013e31825dce03","volume":"3","author":"S Knudsen","year":"2012","unstructured":"Knudsen S, Biering-S\u00f8rensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, Mignot E, Jennum PJ (2012) Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology 3:102\u2013103. https:\/\/doi.org\/10.1212\/WNL.0b013e31825dce03","journal-title":"Neurology"},{"key":"1894_CR92","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5664\/jcsm.6500","volume":"15","author":"M Lecendreux","year":"2017","unstructured":"Lecendreux M, Berthier J, Corny J, Bourdon O, Dossier C, Delclaux C (2017) Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study. J Clin Sleep Med 15:441\u2013453. https:\/\/doi.org\/10.5664\/jcsm.6500","journal-title":"J Clin Sleep Med"},{"key":"1894_CR93","doi-asserted-by":"publisher","unstructured":"Ruppert E, Zagala H, Chambe J, Comtet H, Kilic-Huck U, Lefebvre F, Bataillard M, Schroder C, Calvel L, Bourgin P (2018) Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. BehavNeurol15;2018:1671072. https:\/\/doi.org\/10.1155\/2018\/1671072","DOI":"10.1155\/2018\/1671072"},{"key":"1894_CR94","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1093\/brain\/awt277","volume":"136","author":"F Pizza","year":"2013","unstructured":"Pizza F, Franceschini C, Peltola H (2013) Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136:3787\u20133795. https:\/\/doi.org\/10.1093\/brain\/awt277","journal-title":"Brain"},{"key":"1894_CR95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-4419-0854-4_19","volume-title":"Narcolepsy: a clinical guide","author":"C Donjacour","year":"2010","unstructured":"Donjacour C, Mets MAJ, Verster JC (2010) Narcolepsy, driving and traffic safety. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 217\u2013222"},{"key":"1894_CR96","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-4419-0854-4_18","volume-title":"Narcolepsy: a clinical guide","author":"G Lindsley","year":"2010","unstructured":"Lindsley G (2010) Narcolepsy, intimacy and sexuality. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 205\u2013216"},{"key":"1894_CR97","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2869.2006.00533.x","volume":"15","author":"A Naumann","year":"2006","unstructured":"Naumann A, Bellebaum C, Daum I (2006) Cognitive deficits in narcolepsy. J Sleep Res 15:329\u2013338. https:\/\/doi.org\/10.1111\/j.1365-2869.2006.00533.x","journal-title":"J Sleep Res"},{"key":"1894_CR98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-4419-0854-4_20","volume-title":"Narcolepsy: a clinical guide","author":"C Bellebaum","year":"2010","unstructured":"Bellebaum C, Daum I (2010) Memory and cognition in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 223\u2013230"},{"key":"1894_CR99","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sleep.2010.07.008","volume":"12","author":"L Vignatelli","year":"2011","unstructured":"Vignatelli L, Plazzi G, Peschechera F, Delaj L, D\u2019Alessandro R (2011) A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med 12:19\u201323. https:\/\/doi.org\/10.1016\/j.sleep.2010.07.008","journal-title":"Sleep Med"},{"key":"1894_CR100","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-1-4419-0854-4_21","volume-title":"Narcolepsy: a clinical guide","author":"F Ingravallo","year":"2010","unstructured":"Ingravallo F, Plazzi G (2010) Medico-legal aspects of disability in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 231\u2013238"},{"key":"1894_CR101","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-1-4419-0854-4_22","volume-title":"Narcolepsy: a clinical guide","author":"J Shneerson","year":"2010","unstructured":"Shneerson J (2010) Narcolepsy and mental health. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 239\u2013250"},{"key":"1894_CR102","volume-title":"Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-based guidelines for the UK with graded recommendations","author":"T Britton","year":"2002","unstructured":"Britton T, Hansen A, Hicks J, Howard R, Meredith A (2002) Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-based guidelines for the UK with graded recommendations. Taylor Patten Communications Ltd, Ashtead"},{"key":"1894_CR103","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/sleep\/9.1.167","volume":"9","author":"M Billiard","year":"1986","unstructured":"Billiard M, QueraSalva M, de Koninck J, Besset A, Touchon J, Cahilhac J (1986) Daytime sleep characteristics and night sleep in the narcoleptic patient. Sleep 9:167\u2013174. https:\/\/doi.org\/10.1093\/sleep\/9.1.167","journal-title":"Sleep"},{"key":"1894_CR104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jsmc.2012.03.013","volume":"7","author":"S Overeem","year":"2012","unstructured":"Overeem S, Reading P, Bassetti CL (2012) Narcolepsy. Sleep Med Clin 7:263\u2013281","journal-title":"Sleep Med Clin"},{"key":"1894_CR105","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5664\/jcsm.4554","volume":"11","author":"LE Krahn","year":"2015","unstructured":"Krahn LE, Hershner S, Loeding LD, Maski KP, Rifkin DI, Selim B, Watson NF (2015) Quality measures for the care of patients with narcolepsy. J Clin Sleep Med 11:335. https:\/\/doi.org\/10.5664\/jcsm.4554","journal-title":"J Clin Sleep Med"},{"key":"1894_CR106","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/sleep\/16.5.444","volume":"16","author":"J Mullington","year":"1993","unstructured":"Mullington J, Broughton R (1993) Scheduled naps in the management of daytime sleepiness in narcolepsy cataplexy. Sleep 16:444\u2013456. https:\/\/doi.org\/10.1093\/sleep\/16.5.444","journal-title":"Sleep"},{"key":"1894_CR107","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/0013-4694(94)90071-X","volume":"91","author":"MG Yuchiyama","year":"1994","unstructured":"Yuchiyama MG, Mayer G, Meier-Ewert K (1994) Differential effects of extended sleep in narcoleptics patients. Electroencephalogr Clin Neurophysiol 91:212\u2013218","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"1894_CR108","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5935\/1984-0063.20170004","volume":"10","author":"J Bhattarai","year":"2017","unstructured":"Bhattarai J, Sumerall S (2017) Current and future treatment options for narcolepsy: a review. Sleep Sci 10:19\u201327. https:\/\/doi.org\/10.5935\/1984-0063.20170004","journal-title":"Sleep Sci"},{"key":"1894_CR109","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/01376517-198412000-00009","volume":"16","author":"AE Rogers","year":"1984","unstructured":"Rogers AE (1984) Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs 16:326\u2013334","journal-title":"J Neurosurg Nurs"},{"key":"1894_CR110","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1071\/PY01003","volume":"7","author":"D Bruck","year":"2001","unstructured":"Bruck D, Broughton R (2001) Achieving control over sleepiness in narcolepsy. Aust J Prim Health 7:16\u201324","journal-title":"Aust J Prim Health"},{"key":"1894_CR111","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.slsci.2014.07.023","volume":"12","author":"H Marin-Agudelo","year":"2011","unstructured":"Marin-Agudelo H (2011) Multicomponent cognitive behavioral treatment efficacy for narcolepsy (MCBT-N). Sleep Med 12:S55\u2013S42. https:\/\/doi.org\/10.1016\/j.slsci.2014.07.023","journal-title":"Sleep Med"},{"key":"1894_CR112","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jsmc.2012.03.005","volume":"7","author":"DA Conroy","year":"2012","unstructured":"Conroy DA, Novick DM, Swanson LM (2012) Behavioral management of hypersomnia. Sleep Med Clin 7:325\u2013331","journal-title":"Sleep Med Clin"},{"key":"1894_CR113","first-page":"A275","volume":"35","author":"H Mar\u00edn-Agudelo","year":"2012","unstructured":"Mar\u00edn-Agudelo H, Jim\u00e9nez Correa U (2012) Scheduled naps and systematic desensitization in the emotional processing in patients with narcolepsy: a comparative study of autonomic and cognitive evoked potentials. Sleep 35:A275","journal-title":"Sleep"},{"key":"1894_CR114","unstructured":"Mar\u00edn-Agudelo H, Jim\u00e9nez Correa U (2013) Beliefs and dysfunctional attitudes in patients with narcolepsy; double-blind study of treatment efficacy. Sleep 36(Suppl: A256)"},{"key":"1894_CR115","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/sleep\/30.11.1417","volume":"30","author":"RA Espana","year":"2007","unstructured":"Espana RA, McCormack SL, Mochizuki T, Scammell TE (2007) Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30:1417\u20131425. https:\/\/doi.org\/10.1093\/sleep\/30.11.1417","journal-title":"Sleep"},{"key":"1894_CR116","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fneur.2018.00707","volume":"9","author":"M Filardi","year":"2018","unstructured":"Filardi M, Pizza F, Antelmi E, Pillastrini P, Natale V, Plazzi G (2018) Physical activity and sleep\/wake behavior, anthropometric, and metabolic profile in pediatric narcolepsy type 1. Front Neurol 9:707. https:\/\/doi.org\/10.3389\/fneur.2018.00707","journal-title":"Front Neurol"},{"key":"1894_CR117","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.slsci.2014.07.023","volume":"7","author":"HA Mar\u00ednAgudelo","year":"2014","unstructured":"Mar\u00ednAgudelo HA, Jim\u00e9nez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH (2014) Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy? Sleep Sci 7:30\u201342. https:\/\/doi.org\/10.1016\/j.slsci.2014.07.023","journal-title":"Sleep Sci"},{"key":"1894_CR118","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0020-7489(02)00092-5","volume":"40","author":"CL Dennis","year":"2003","unstructured":"Dennis CL (2003) Peer support within a health care context: a concept analysis. Int J Nurs Stud 40:321\u2013332. https:\/\/doi.org\/10.1016\/S0020-7489(02)00092-5","journal-title":"Int J Nurs Stud"},{"key":"1894_CR119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pec.2013.02.002","volume":"92","author":"G Embuldeniya","year":"2013","unstructured":"Embuldeniya G, Veinot P, Bell E, Nyhof-Young J, Sale JE, Britten N (2013) The experience and impact of chronic disease peer support interventions: a qualitative synthesis. Patient Educ Couns 92:3\u201312. https:\/\/doi.org\/10.1016\/j.pec.2013.02.002","journal-title":"Patient Educ Couns"},{"key":"1894_CR120","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dmcn.12091","volume":"55","author":"V Shilling","year":"2013","unstructured":"Shilling V, Morris C, Thompson-Coon J, Ukoumunne O, Rogers M, Logan S (2013) Peer support for parents of children with chronic disabling conditions: a systematic review of quantitative and qualitative studies. Dev Med Child Neurol 55:602\u2013609. https:\/\/doi.org\/10.1111\/dmcn.12091","journal-title":"Dev Med Child Neurol"},{"key":"1894_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-22","volume":"8","author":"M Anderson","year":"2013","unstructured":"Anderson M, Elliott EJ, Zurynski YA (2013) Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis 8:1\u20139. https:\/\/doi.org\/10.1186\/1750-1172-8-22","journal-title":"Orphanet J Rare Dis"},{"key":"1894_CR122","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/1367493516643420","volume":"20","author":"A Kippola-P\u00e4\u00e4kk\u00f6nen","year":"2016","unstructured":"Kippola-P\u00e4\u00e4kk\u00f6nen A, H\u00e4rk\u00e4p\u00e4\u00e4 K, Valkonen J, Tuulio-Henriksson A, Autti-R\u00e4m\u00f6 I (2016) Psychosocial intervention for children with narcolepsy: parents\u2019 expectations and perceived support. J Child Health Care 20:521\u2013529. https:\/\/doi.org\/10.1177\/1367493516643420","journal-title":"J Child Health Care"},{"key":"1894_CR123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.sleep.2017.07.030","volume":"40","author":"Y Dauvilliers","year":"2017","unstructured":"Dauvilliers Y, Roth T, Giunta D et al (2017) Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med 40:53\u201357. https:\/\/doi.org\/10.1016\/j.sleep.2017.07.030","journal-title":"Sleep Med"},{"key":"1894_CR124","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, Zee P (2013) Disrupted nighttime sleep in narcolepsy. J Clin Sleep 9:955\u2013965. https:\/\/doi.org\/10.5664\/jcsm.3004","journal-title":"J Clin Sleep"},{"key":"1894_CR125","unstructured":"European Commission (2014) Implementation report on the commission communication on rare diseases: Europe\u2019s challenges and council recommendation of 8 June 2009 on an action in the field of rare diseases. Available at: http:\/\/ec.europa.eu\/health\/rare_diseases\/docs\/2014_rarediseases_implementationreport_en.pdf"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-019-01894-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-019-01894-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-019-01894-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:21:22Z","timestamp":1744176082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-019-01894-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1007\/s11325-019-01894-4","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The work is a literature review and complied with the tenets of the Declaration of Helsinki, as well as with the ethical standards of the journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards\u00a0"}},{"value":"\u00a0Giuseppe Plazzi participated in advisory board for UCB Pharma, Jazz pharmaceuticals, Bioprojet, and Idorsia outside the submitted work. The other authors have no potential financial conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}